VRDN Quote, Financials, Valuation and Earnings

Avantor, Inc. has a net margin of -49.03% compared to Viridian Therapeutics, Inc.'s net margin of -43.84%. Viridian Therapeutics, Inc.'s return on equity of -47.79% beat Avantor, Inc.'s return on equity of -1.4%.

Viridian Therapeutics, Inc. has a consensus price target of $41.25, signalling upside risk potential of 29.39%. On the other hand Avantor, Inc. has an analysts' consensus of $13.32 which suggests that it could grow by 16.55%. Given that Viridian Therapeutics, Inc. has higher upside potential than Avantor, Inc., analysts believe Viridian Therapeutics, Inc. is more attractive than Avantor, Inc..

Viridian Therapeutics, Inc. has a beta of 0.914, which suggesting that the stock is 8.612% less volatile than S&P 500. In comparison Avantor, Inc. has a beta of 0.930, suggesting its less volatile than the S&P 500 by 7.02%.

Viridian Therapeutics, Inc. has a quarterly dividend of $0.00 per share corresponding to a yield of 0%. Avantor, Inc. offers a yield of 0% to investors and pays a quarterly dividend of $0.00 per share. Viridian Therapeutics, Inc. pays -- of its earnings as a dividend. Avantor, Inc. pays out -- of its earnings as a dividend.

Viridian Therapeutics, Inc. quarterly revenues are $70.6M, which are smaller than Avantor, Inc. quarterly revenues of $1.6B. Viridian Therapeutics, Inc.'s net income of -$34.6M is higher than Avantor, Inc.'s net income of -$711.8M. Notably, Viridian Therapeutics, Inc.'s price-to-earnings ratio is -- while Avantor, Inc.'s PE ratio is 10.97x. Generally a lower price-to-earnings ratio signals a stock is trading at a lower multiple of earnings and is a better value. Another key metric is the price-to-sales ratio, which for Viridian Therapeutics, Inc. is 36.57x versus 1.19x for Avantor, Inc.. Usually stocks with elevated PS ratios are considered overvalued.

Perspective Therapeutics, Inc. has a net margin of -49.03% compared to Viridian Therapeutics, Inc.'s net margin of -12425.36%. Viridian Therapeutics, Inc.'s return on equity of -47.79% beat Perspective Therapeutics, Inc.'s return on equity of -37.63%.

Viridian Therapeutics, Inc. has a consensus price target of $41.25, signalling upside risk potential of 29.39%. On the other hand Perspective Therapeutics, Inc. has an analysts' consensus of $12.3077 which suggests that it could grow by 327.35%. Given that Perspective Therapeutics, Inc. has higher upside potential than Viridian Therapeutics, Inc., analysts believe Perspective Therapeutics, Inc. is more attractive than Viridian Therapeutics, Inc..

Viridian Therapeutics, Inc. has a beta of 0.914, which suggesting that the stock is 8.612% less volatile than S&P 500. In comparison Perspective Therapeutics, Inc. has a beta of 1.222, suggesting its more volatile than the S&P 500 by 22.249%.

Viridian Therapeutics, Inc. has a quarterly dividend of $0.00 per share corresponding to a yield of 0%. Perspective Therapeutics, Inc. offers a yield of 0% to investors and pays a quarterly dividend of $0.00 per share. Viridian Therapeutics, Inc. pays -- of its earnings as a dividend. Perspective Therapeutics, Inc. pays out -- of its earnings as a dividend.

Viridian Therapeutics, Inc. quarterly revenues are $70.6M, which are larger than Perspective Therapeutics, Inc. quarterly revenues of $209K. Viridian Therapeutics, Inc.'s net income of -$34.6M is lower than Perspective Therapeutics, Inc.'s net income of -$26M. Notably, Viridian Therapeutics, Inc.'s price-to-earnings ratio is -- while Perspective Therapeutics, Inc.'s PE ratio is --. Generally a lower price-to-earnings ratio signals a stock is trading at a lower multiple of earnings and is a better value. Another key metric is the price-to-sales ratio, which for Viridian Therapeutics, Inc. is 36.57x versus 195.28x for Perspective Therapeutics, Inc.. Usually stocks with elevated PS ratios are considered overvalued.

Immunovant, Inc. has a net margin of -49.03% compared to Viridian Therapeutics, Inc.'s net margin of --. Viridian Therapeutics, Inc.'s return on equity of -47.79% beat Immunovant, Inc.'s return on equity of -88.1%.

Viridian Therapeutics, Inc. has a consensus price target of $41.25, signalling upside risk potential of 29.39%. On the other hand Immunovant, Inc. has an analysts' consensus of $39.27 which suggests that it could grow by 50.1%. Given that Immunovant, Inc. has higher upside potential than Viridian Therapeutics, Inc., analysts believe Immunovant, Inc. is more attractive than Viridian Therapeutics, Inc..

Viridian Therapeutics, Inc. has a beta of 0.914, which suggesting that the stock is 8.612% less volatile than S&P 500. In comparison Immunovant, Inc. has a beta of 0.557, suggesting its less volatile than the S&P 500 by 44.254%.

Viridian Therapeutics, Inc. has a quarterly dividend of $0.00 per share corresponding to a yield of 0%. Immunovant, Inc. offers a yield of 0% to investors and pays a quarterly dividend of $0.00 per share. Viridian Therapeutics, Inc. pays -- of its earnings as a dividend. Immunovant, Inc. pays out -- of its earnings as a dividend.

Viridian Therapeutics, Inc. quarterly revenues are $70.6M, which are larger than Immunovant, Inc. quarterly revenues of --. Viridian Therapeutics, Inc.'s net income of -$34.6M is higher than Immunovant, Inc.'s net income of -$126.5M. Notably, Viridian Therapeutics, Inc.'s price-to-earnings ratio is -- while Immunovant, Inc.'s PE ratio is --. Generally a lower price-to-earnings ratio signals a stock is trading at a lower multiple of earnings and is a better value. Another key metric is the price-to-sales ratio, which for Viridian Therapeutics, Inc. is 36.57x versus -- for Immunovant, Inc.. Usually stocks with elevated PS ratios are considered overvalued.

Orthofix Medical, Inc. has a net margin of -49.03% compared to Viridian Therapeutics, Inc.'s net margin of -11.09%. Viridian Therapeutics, Inc.'s return on equity of -47.79% beat Orthofix Medical, Inc.'s return on equity of -24.94%.

Viridian Therapeutics, Inc. has a consensus price target of $41.25, signalling upside risk potential of 29.39%. On the other hand Orthofix Medical, Inc. has an analysts' consensus of $22.80 which suggests that it could grow by 49.61%. Given that Orthofix Medical, Inc. has higher upside potential than Viridian Therapeutics, Inc., analysts believe Orthofix Medical, Inc. is more attractive than Viridian Therapeutics, Inc..

Viridian Therapeutics, Inc. has a beta of 0.914, which suggesting that the stock is 8.612% less volatile than S&P 500. In comparison Orthofix Medical, Inc. has a beta of 0.819, suggesting its less volatile than the S&P 500 by 18.057%.

Viridian Therapeutics, Inc. has a quarterly dividend of $0.00 per share corresponding to a yield of 0%. Orthofix Medical, Inc. offers a yield of 0% to investors and pays a quarterly dividend of $0.00 per share. Viridian Therapeutics, Inc. pays -- of its earnings as a dividend. Orthofix Medical, Inc. pays out -- of its earnings as a dividend.

Viridian Therapeutics, Inc. quarterly revenues are $70.6M, which are smaller than Orthofix Medical, Inc. quarterly revenues of $205.6M. Viridian Therapeutics, Inc.'s net income of -$34.6M is lower than Orthofix Medical, Inc.'s net income of -$22.8M. Notably, Viridian Therapeutics, Inc.'s price-to-earnings ratio is -- while Orthofix Medical, Inc.'s PE ratio is --. Generally a lower price-to-earnings ratio signals a stock is trading at a lower multiple of earnings and is a better value. Another key metric is the price-to-sales ratio, which for Viridian Therapeutics, Inc. is 36.57x versus 0.73x for Orthofix Medical, Inc.. Usually stocks with elevated PS ratios are considered overvalued.